BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schönekäs H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006;24:3946-3952. [PMID: 16921047 DOI: 10.1200/jco.2005.05.1490] [Cited by in Crossref: 448] [Cited by in F6Publishing: 218] [Article Influence: 28.0] [Reference Citation Analysis]
Number Citing Articles
1 Kindler HL. Pancreatic cancer: an update. Curr Oncol Rep 2007;9:170-6. [PMID: 17430687 DOI: 10.1007/s11912-007-0018-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
2 Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010;28:3617-3622. [PMID: 20606091 DOI: 10.1200/jco.2010.28.1386] [Cited by in Crossref: 562] [Cited by in F6Publishing: 331] [Article Influence: 46.8] [Reference Citation Analysis]
3 van Tienhoven G, Gouma DJ, Richel DJ. Neoadjuvant chemoradiotherapy has a potential role in pancreatic carcinoma. Ther Adv Med Oncol 2011;3:27-33. [PMID: 21789153 DOI: 10.1177/1758834010383150] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
4 Brunner M, Wu Z, Krautz C, Pilarsky C, Grützmann R, Weber GF. Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions. Int J Mol Sci 2019;20:E4543. [PMID: 31540286 DOI: 10.3390/ijms20184543] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
5 Huang P, Zhong XY, Xu Y, Cui YF. Role of neoadjuvant therapy and adjuvant therapy in treatment of pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2013; 21(14): 1292-1296 [DOI: 10.11569/wcjd.v21.i14.1292] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Wysocka O, Kulbacka J, Saczko J. Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinoma. Prz Gastroenterol 2016;11:155-62. [PMID: 27713776 DOI: 10.5114/pg.2016.61438] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
7 Bruera G, Massacese S, Candria S, Galvano A, Manetta R, Giordano AV, Carducci S, Di Sibio A, Ciacco E, Russo A, Ricevuto E; Oncology Network ASL1 Abruzzo, Italy. Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II study. Oncotarget 2018;9:31861-76. [PMID: 30159128 DOI: 10.18632/oncotarget.25870] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
8 Buc E, Orry D, Antomarchi O, Gagnière J, Da Ines D, Pezet D. Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile? World J Surg Oncol 2014;12:347. [PMID: 25407113 DOI: 10.1186/1477-7819-12-347] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
9 Kutkowska J, Strzadala L, Rapak A. Sorafenib in Combination with Betulinic Acid Synergistically Induces Cell Cycle Arrest and Inhibits Clonogenic Activity in Pancreatic Ductal Adenocarcinoma Cells. Int J Mol Sci 2018;19:E3234. [PMID: 30347681 DOI: 10.3390/ijms19103234] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
10 Ghosn M, Kourie HR, El Rassy E, Haddad FG, Hanna C, El Karak F, Nasr D. Where does chemotherapy stands in the treatment of ampullary carcinoma? A review of literature. World J Gastrointest Oncol 2016; 8(10): 745-750 [PMID: 27795814 DOI: 10.4251/wjgo.v8.i10.745] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
11 Koutsounas I, Giaginis C, Patsouris E, Theocharis S. Current evidence for histone deacetylase inhibitors in pancreatic cancer. World J Gastroenterol 2013; 19(6): 813-828 [PMID: 23430136 DOI: 10.3748/wjg.v19.i6.813] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
12 Desai NV, Sliesoraitis S, Hughes SJ, Trevino JG, Zlotecki RA, Ivey AM, George TJ Jr. Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer. Cancer Med 2015;4:1224-39. [PMID: 25766842 DOI: 10.1002/cam4.444] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
13 Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607-620. [PMID: 21620466 DOI: 10.1016/so140-6736(10)62307-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Kim H, Zhai G, Liu Z, Samuel S, Shah N, Helman EE, Knowles JA, Stockard CR, Fineberg NS, Grizzle WE, Zhou T, Zinn KR, Rosenthal EL. Extracelluar matrix metalloproteinase as a novel target for pancreatic cancer therapy. Anticancer Drugs 2011;22:864-74. [PMID: 21730821 DOI: 10.1097/CAD.0b013e328349311e] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
15 Polireddy K, Chen Q. Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment. J Cancer 2016;7:1497-514. [PMID: 27471566 DOI: 10.7150/jca.14922] [Cited by in Crossref: 35] [Cited by in F6Publishing: 41] [Article Influence: 5.8] [Reference Citation Analysis]
16 Epelbaum R, Shacham-Shmueli E, Klein B, Agbarya A, Brenner B, Brenner R, Gez E, Golan T, Hubert A, Purim O, Temper M, Tepper E, Voss A, Russell K, Dvir A, Soussan-Gutman L, Stemmer SM, Geva R. Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study. Biomed Res Int 2015;2015:681653. [PMID: 26161408 DOI: 10.1155/2015/681653] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
17 Spano JP, Moore MJ, Pithavala YK, Ricart AD, Kim S, Rixe O. Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer. Invest New Drugs 2012;30:1531-9. [PMID: 21670972 DOI: 10.1007/s10637-011-9697-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
18 Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. The Lancet 2004;363:1049-57. [DOI: 10.1016/s0140-6736(04)15841-8] [Cited by in Crossref: 1360] [Cited by in F6Publishing: 672] [Article Influence: 75.6] [Reference Citation Analysis]
19 Chan SL, Chan ST, Chan EH, He ZX. Systemic treatment for inoperable pancreatic adenocarcinoma: review and update. Chin J Cancer 2014;33:267-76. [PMID: 24472302 DOI: 10.5732/cjc.013.10134] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
20 Chen J, Chen L, Yu J, Xu Y, Wang X, Zeng Z, Liu N, Xu F, Yang S. Meta‑analysis of current chemotherapy regimens in advanced pancreatic cancer to prolong survival and reduce treatment‑associated toxicities. Mol Med Rep 2019;19:477-89. [PMID: 30431091 DOI: 10.3892/mmr.2018.9638] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Mao YH, Yu CZ. Current situation and predicament of multidisciplinary treatment of pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2015; 23(36): 5750-5759 [DOI: 10.11569/wcjd.v23.i36.5750] [Reference Citation Analysis]
22 Akita H, Zheng Z, Takeda Y, Kim C, Kittaka N, Kobayashi S, Marubashi S, Takemasa I, Nagano H, Dono K, Nakamori S, Monden M, Mori M, Doki Y, Bepler G. Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene. 2009;28:2903-2909. [PMID: 19543324 DOI: 10.1038/onc.2009.158] [Cited by in Crossref: 84] [Cited by in F6Publishing: 82] [Article Influence: 6.5] [Reference Citation Analysis]
23 Ozaki T, Yu M, Yin D, Sun D, Zhu Y, Bu Y, Sang M. Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations. BMC Cancer 2018;18:309. [PMID: 29558908 DOI: 10.1186/s12885-018-4217-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
24 Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, Hruban RH. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63:318-348. [PMID: 23856911 DOI: 10.3322/caac.21190] [Cited by in Crossref: 479] [Cited by in F6Publishing: 473] [Article Influence: 53.2] [Reference Citation Analysis]
25 Chawla SP, Bruckner H, Morse MA, Assudani N, Hall FL, Gordon EM. A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer. Mol Ther Oncolytics 2019;12:56-67. [PMID: 30705966 DOI: 10.1016/j.omto.2018.12.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
26 Valenzuela MM, Neidigh JW, Wall NR. Antimetabolite Treatment for Pancreatic Cancer. Chemotherapy (Los Angel) 2014;3:137. [PMID: 26161298 DOI: 10.4172/2167-7700.1000137] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
27 Samanta K, Setua S, Kumari S, Jaggi M, Yallapu MM, Chauhan SC. Gemcitabine Combination Nano Therapies for Pancreatic Cancer. Pharmaceutics. 2019;11. [PMID: 31689930 DOI: 10.3390/pharmaceutics11110574] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
28 Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer. 2008;8:82. [PMID: 18373843 DOI: 10.1186/11471-2407-8-82] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Zhang S, Xie W, Zou Y, Xie S, Zhang J, Yuan W, Ma J, Zhao J, Zheng C, Chen Y, Wang C. First-line chemotherapy regimens for locally advanced and metastatic pancreatic adenocarcinoma: a Bayesian analysis. Cancer Manag Res 2018;10:5965-78. [PMID: 30538546 DOI: 10.2147/CMAR.S162980] [Reference Citation Analysis]
30 Sohn BS, Yuh YJ, Song HS, Kim BS, Lee KH, Jang JS, Kim SR. Triplet cytotoxic chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced pancreatic cancer. Oncol Lett 2015;10:1204-10. [PMID: 26622653 DOI: 10.3892/ol.2015.3347] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
31 Dakik HK, Moskovic DJ, Carlson PJ, Tamm EP, Qiao W, Wolff RA, Abbruzzese JL, Fogelman DR. The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol. 2012;69:425-430. [PMID: 21850466 DOI: 10.1007/s00280-011-1705-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
32 Wilkowski R, Boeck S, Ostermaier S, Sauer R, Herbst M, Fietkau R, Flentje M, Miethe S, Boettcher HD, Scholten T, Bruns CJ, Rau HG, Hinke A, Heinemann V. Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer--a multi-centre randomised phase II study. Br J Cancer 2009;101:1853-9. [PMID: 19904268 DOI: 10.1038/sj.bjc.6605420] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
33 Martin LK, Wei L, Trolli E, Bekaii-Saab T. Elevated baseline CA19-9 levels correlate with adverse prognosis in patients with early- or advanced-stage pancreas cancer. Med Oncol. 2012;29:3101-3107. [PMID: 22729400 DOI: 10.1007/s12032-012-0278-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
34 Sugimoto H, Nakamura M, Yoda H, Hiraoka K, Shinohara K, Sang M, Fujiwara K, Shimozato O, Nagase H, Ozaki T. Silencing of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death. Cell Death Discov 2015;1:15010. [PMID: 27551445 DOI: 10.1038/cddiscovery.2015.10] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
35 Altwegg R, Ychou M, Guillaumon V, Thezenas S, Senesse P, Flori N, Mazard T, Caillo L, Faure S, Samalin E, Assenat E. Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer. World J Gastroenterol 2012; 18(12): 1357-1364 [PMID: 22493549 DOI: 10.3748/wjg.v18.i12.1357] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
36 Borsoi C, Leonard F, Lee Y, Zaid M, Elganainy D, Alexander JF, Kai M, Liu YT, Kang Y, Liu X, Koay EJ, Ferrari M, Godin B, Yokoi K. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma. Cancer Lett 2017;403:296-304. [PMID: 28687352 DOI: 10.1016/j.canlet.2017.06.026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
37 Sohal DP, Mangu PB, Khorana AA, Shah MA, Philip PA, O'Reilly EM, Uronis HE, Ramanathan RK, Crane CH, Engebretson A, Ruggiero JT, Copur MS, Lau M, Urba S, Laheru D. Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34:2784-2796. [PMID: 27247222 DOI: 10.1200/jco.2016.67.1412] [Cited by in Crossref: 166] [Cited by in F6Publishing: 90] [Article Influence: 27.7] [Reference Citation Analysis]
38 Lo Re G, Santeufemia DA, Foltran L, Bidoli E, Basso SM, Lumachi F. Prognostic factors of survival in patients treated with nab-paclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: a single institutional experience. Oncotarget 2015;6:8255-60. [PMID: 25779664 DOI: 10.18632/oncotarget.3143] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
39 Forero-Torres A, Infante JR, Waterhouse D, Wong L, Vickers S, Arrowsmith E, He AR, Hart L, Trent D, Wade J, Jin X, Wang Q, Austin T, Rosen M, Beckman R, von Roemeling R, Greenberg J, Saleh M. Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer. Cancer Med 2013;2:925-32. [PMID: 24403266 DOI: 10.1002/cam4.137] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 6.4] [Reference Citation Analysis]
40 Javle M, Yu J, Garrett C, Pande A, Kuvshinoff B, Litwin A, Phelan J 3rd, Gibbs J, Iyer R. Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study. Br J Cancer 2009;100:1842-5. [PMID: 19491904 DOI: 10.1038/sj.bjc.6605099] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
41 Long J, Zhang Y, Yu X, Yang J, LeBrun DG, Chen C, Yao Q, Li M. Overcoming drug resistance in pancreatic cancer. Expert Opin Ther Targets. 2011;15:817-828. [PMID: 21391891 DOI: 10.1517/14728222.2011.566216] [Cited by in Crossref: 132] [Cited by in F6Publishing: 133] [Article Influence: 12.0] [Reference Citation Analysis]
42 Kang MJ, Jang JY, Lee SE, Lim CS, Lee KU, Kim SW. Comparison of the long-term outcomes of uncinate process cancer and non-uncinate process pancreas head cancer: poor prognosis accompanied by early locoregional recurrence. Langenbecks Arch Surg. 2010;395:697-706. [PMID: 20652784 DOI: 10.1007/s00423-010-0593-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
43 Han B, Kim BJ, Kim HS, Choi DR, Shim BY, Lee KH, Kim JW, Kim JH, Song H, Kim JH, Park CK, Lee JW, Kim MJ, Zang DY. A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer. J Cancer 2021;12:912-7. [PMID: 33403047 DOI: 10.7150/jca.50514] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Sugarbaker PH, Stuart OA, Bijelic L. Intraperitoneal gemcitabine chemotherapy treatment for patients with resected pancreatic cancer: rationale and report of early data. Int J Surg Oncol 2011;2011:161862. [PMID: 22312494 DOI: 10.1155/2011/161862] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
45 Patel K, Kollory A, Takashima A, Sarkar S, Faller DV, Ghosh SK. MicroRNA let-7 downregulates STAT3 phosphorylation in pancreatic cancer cells by increasing SOCS3 expression. Cancer Lett. 2014;347:54-64. [PMID: 24491408 DOI: 10.1016/j.canlet.2014.01.020] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 6.4] [Reference Citation Analysis]
46 Hong SP, Park JY, Jeon TJ, Bang S, Park SW, Chung JB, Park MS, Seong J, Lee WJ, Song SY. Weekly full-dose gemcitabine and single-dose cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer. Br J Cancer. 2008;98:881-887. [PMID: 18301403 DOI: 10.1038/sj.bjc.6604247] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
47 Fesler A, Ju J. Development of microRNA-based therapy for pancreatic cancer. J Pancreatol 2019;2:147-51. [PMID: 32133215 DOI: 10.1097/jp9.0000000000000029] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
48 Parkin A, Man J, Chou A, Nagrial AM, Samra J, Gill AJ, Timpson P, Pajic M. The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma. Diseases 2018;6:E103. [PMID: 30428574 DOI: 10.3390/diseases6040103] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
49 Poruk KE, Firpo MA, Adler DG, Mulvihill SJ. Screening for pancreatic cancer: why, how, and who? Ann Surg 2013;257:17-26. [PMID: 22895395 DOI: 10.1097/SLA.0b013e31825ffbfb] [Cited by in Crossref: 120] [Cited by in F6Publishing: 64] [Article Influence: 13.3] [Reference Citation Analysis]
50 Moss RA, Lee C. Current and emerging therapies for the treatment of pancreatic cancer. Onco Targets Ther 2010;3:111-27. [PMID: 20856847 DOI: 10.2147/ott.s7203] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
51 Bauer TM, El-Rayes BF, Li X, Hammad N, Philip PA, Shields AF, Zalupski MM, Bekaii-Saab T. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials. Cancer. 2013;119:285-292. [PMID: 22786786 DOI: 10.1002/cncr.27734] [Cited by in Crossref: 70] [Cited by in F6Publishing: 70] [Article Influence: 7.0] [Reference Citation Analysis]
52 Herreros-Villanueva M, Hijona E, Cosme A, Bujanda L. Adjuvant and neoadjuvant treatment in pancreatic cancer. World J Gastroenterol 2012; 18(14): 1565-1572 [PMID: 22529684 DOI: 10.3748/wjg.v18.i14.1565] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
53 Okamoto Y, Maeba T, Kakinoki K, Okano K, Izuishi K, Wakabayashi H, Usuki H, Suzuki Y. A patient with unresectable advanced pancreatic cancer achieving long-term survival with gemcitabine chemotherapy. World J Gastroenterol. 2008;14:6876-6880. [PMID: 19058319 DOI: 10.3748/wjg.14.6876] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
54 Yang SH, Lee JC, Guo JC, Kuo SH, Tien YW, Kuo TC, Cheng AL, Yeh KH. Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy. PLoS One 2017;12:e0180628. [PMID: 28678832 DOI: 10.1371/journal.pone.0180628] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
55 Oberoi HS, Nukolova NV, Kabanov AV, Bronich TK. Nanocarriers for delivery of platinum anticancer drugs. Adv Drug Deliv Rev 2013;65:1667-85. [PMID: 24113520 DOI: 10.1016/j.addr.2013.09.014] [Cited by in Crossref: 258] [Cited by in F6Publishing: 223] [Article Influence: 28.7] [Reference Citation Analysis]
56 Fotopoulos G, Syrigos K, Saif MW. Genetic factors affecting patient responses to pancreatic cancer treatment. Ann Gastroenterol 2016;29:466-76. [PMID: 27708512 DOI: 10.20524/aog.2016.0056] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
57 Awasthi N, Schwarz MA, Schwarz RE. Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer. HPB (Oxford) 2011;13:597-604. [PMID: 21843259 DOI: 10.1111/j.1477-2574.2011.00333.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
58 Mian OY, Ram AN, Tuli R, Herman JM. Management options in locally advanced pancreatic cancer. Curr Oncol Rep 2014;16:388. [PMID: 24740136 DOI: 10.1007/s11912-014-0388-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
59 Kanji ZS, Gallinger S. Diagnosis and management of pancreatic cancer. CMAJ. 2013;185:1219-1226. [PMID: 23610017 DOI: 10.1503/cmaj.121368] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
60 Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010;7:163-72. [DOI: 10.1038/nrclinonc.2009.236] [Cited by in Crossref: 516] [Cited by in F6Publishing: 504] [Article Influence: 43.0] [Reference Citation Analysis]
61 Wu S, Guo J, Wei W, Zhang J, Fang J, Beebe SJ. Enhanced breast cancer therapy with nsPEFs and low concentrations of gemcitabine. Cancer Cell Int 2014;14:98. [PMID: 25379013 DOI: 10.1186/s12935-014-0098-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
62 Monti DA, Mitchell E, Bazzan AJ, Littman S, Zabrecky G, Yeo CJ, Pillai MV, Newberg AB, Deshmukh S, Levine M. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One 2012;7:e29794. [PMID: 22272248 DOI: 10.1371/journal.pone.0029794] [Cited by in Crossref: 138] [Cited by in F6Publishing: 132] [Article Influence: 13.8] [Reference Citation Analysis]
63 O'Reilly EM, Lee JW, Lowery MA, Capanu M, Stadler ZK, Moore MJ, Dhani N, Kindler HL, Estrella H, Maynard H, Golan T, Segal A, Salo-Mullen EE, Yu KH, Epstein AS, Segal M, Brenner R, Do RK, Chen AP, Tang LH, Kelsen DP. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma. Cancer 2018;124:1374-82. [PMID: 29338080 DOI: 10.1002/cncr.31218] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 13.3] [Reference Citation Analysis]
64 Kang CM, Babicky ML, Lowy AM. The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapies. Pancreas. 2014;43:183-189. [PMID: 24518495 DOI: 10.1097/mpa.0000000000000088] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
65 Zhang XW, Ma YX, Sun Y, Cao YB, Li Q, Xu CA. Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis. Target Oncol 2017;12:309-21. [PMID: 28353074 DOI: 10.1007/s11523-017-0486-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
66 Manuel ER, Chen J, D'Apuzzo M, Lampa MG, Kaltcheva TI, Thompson CB, Ludwig T, Chung V, Diamond DJ. Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors. Cancer Immunol Res 2015;3:1096-107. [PMID: 26134178 DOI: 10.1158/2326-6066.CIR-14-0214] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 5.4] [Reference Citation Analysis]
67 Hunsberger S, Zhao Y, Simon R. A comparison of phase II study strategies. Clin Cancer Res 2009;15:5950-5. [PMID: 19789306 DOI: 10.1158/1078-0432.CCR-08-3205] [Cited by in Crossref: 32] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
68 Lee KH, Chie EK, Im SA, Kim JH, Kwon J, Han SW, Oh DY, Jang JY, Kim JS, Kim TY, Bang YJ, Kim SW, Ha SW. Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer. Cancer Res Treat 2020. [PMID: 33421976 DOI: 10.4143/crt.2020.928] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
69 Geng M, Xu H, Ren R, Qu Q, Shangguan C, Wu J, Jiang J, Li H, Cao W. Prognostic value of clinicopathological characteristics in patients with pancreatic cancer. Chin J Cancer Res 2015;27:509-15. [PMID: 26543338 DOI: 10.3978/j.issn.1000-9604.2015.06.03] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
70 Kim H, Samuel S, Lopez-Casas P, Grizzle W, Hidalgo M, Kovar J, Oelschlager D, Zinn K, Warram J, Buchsbaum D. SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts. Mol Cancer Ther. 2016;15:680-688. [PMID: 26832793 DOI: 10.1158/1535-7163.mct-15-0764] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 4.7] [Reference Citation Analysis]
71 Ying JE, Zhu LM, Liu BX. Developments in metastatic pancreatic cancer: Is gemcitabine still the standard? World J Gastroenterol 2012; 18(8): 736-745 [PMID: 22371633 DOI: 10.3748/wjg.v18.i8.736] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 41] [Article Influence: 4.5] [Reference Citation Analysis]
72 Thota R, Maitra A, Berlin JD. Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer? Pancreas 2017;46:143-50. [PMID: 28085753 DOI: 10.1097/MPA.0000000000000753] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
73 Guo JC, Yang SH. Sequential gemcitabine and platinum versus first-line combination of gemcitabine and platinum for advanced pancreatic cancer treatment: a retrospective study. Int J Clin Oncol 2014;19:634-42. [PMID: 24077663 DOI: 10.1007/s10147-013-0622-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
74 Laing RE, Walter MA, Campbell DO, Herschman HR, Satyamurthy N, Phelps ME, Czernin J, Witte ON, Radu CG. Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography. Proc Natl Acad Sci U S A 2009;106:2847-52. [PMID: 19196993 DOI: 10.1073/pnas.0812890106] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 3.6] [Reference Citation Analysis]
75 Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B, Tartakovsky I, Nemunaitis J, Le D, Sugar E, Hege K, Jaffee E. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res. 2008;14:1455-1463. [PMID: 18316569 DOI: 10.1158/1078-0432.ccr-07-0371] [Cited by in Crossref: 225] [Cited by in F6Publishing: 152] [Article Influence: 16.1] [Reference Citation Analysis]
76 Park JO, Oh DY, Hsu C, Chen JS, Chen LT, Orlando M, Kim JS, Lim HY. Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review. Cancer Res Treat 2015;47:343-61. [PMID: 25989801 DOI: 10.4143/crt.2014.308] [Cited by in Crossref: 32] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
77 Luo M, Chen J, Zhong Z, Zhang F. CT-guided 125I brachytherapy combined with chemotherapy for the treatment of unresectable or locally advanced pancreatic carcinoma. Diagn Interv Radiol 2021;27:50-8. [PMID: 33252336 DOI: 10.5152/dir.2020.19371] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
78 Elia A, Henry-Grant R, Adiseshiah C, Marboeuf C, Buckley RJ, Clemens MJ, Mudan S, Pyronnet S. Implication of 4E-BP1 protein dephosphorylation and accumulation in pancreatic cancer cell death induced by combined gemcitabine and TRAIL. Cell Death Dis 2017;8:3204. [PMID: 29233971 DOI: 10.1038/s41419-017-0001-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
79 Li J, Wientjes MG, Au JL. Pancreatic cancer: pathobiology, treatment options, and drug delivery. AAPS J 2010;12:223-32. [PMID: 20198462 DOI: 10.1208/s12248-010-9181-5] [Cited by in Crossref: 68] [Cited by in F6Publishing: 69] [Article Influence: 5.7] [Reference Citation Analysis]
80 Iovanna J, Mallmann MC, Gonçalves A, Turrini O, Dagorn JC. Current knowledge on pancreatic cancer. Front Oncol. 2012;2:6. [PMID: 22655256 DOI: 10.3389/fonc.2012.00006] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 4.5] [Reference Citation Analysis]
81 Asahara S, Takeda K, Yamao K, Maguchi H, Yamaue H. Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer. J Transl Med 2013;11:291. [PMID: 24237633 DOI: 10.1186/1479-5876-11-291] [Cited by in Crossref: 41] [Cited by in F6Publishing: 46] [Article Influence: 4.6] [Reference Citation Analysis]
82 Freidlin B, Korn EL. Monitoring for lack of benefit: a critical component of a randomized clinical trial. J Clin Oncol 2009;27:629-33. [PMID: 19064977 DOI: 10.1200/JCO.2008.17.8905] [Cited by in Crossref: 26] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
83 Ko AH, Youssoufian H, Gurtler J, Dicke K, Kayaleh O, Lenz HJ, Keaton M, Katz T, Ballal S, Rowinsky EK. A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma. Invest New Drugs. 2012;30:1597-1606. [PMID: 21629990 DOI: 10.1007/s10637-011-9691-8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
84 Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008;8:82. [PMID: 18373843 DOI: 10.1186/1471-2407-8-82] [Cited by in Crossref: 280] [Cited by in F6Publishing: 265] [Article Influence: 20.0] [Reference Citation Analysis]
85 Thillai K, Sarker D, Ross P. Progress in pancreatic cancer therapeutics: The potential to exploit molecular targets. World J Pharmacol 2015; 4(2): 180-192 [DOI: 10.5497/wjp.v4.i2.180] [Reference Citation Analysis]
86 Isacoff WH, Reber HA, Bedford R, Hoos W, Rahib L, Upfill-Brown A, Donahue T, Hines OJ. Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis. Target Oncol 2018;13:461-8. [PMID: 29882102 DOI: 10.1007/s11523-018-0572-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
87 Weekes CD, Nallapareddy S, Rudek MA, Norris-Kirby A, Laheru D, Jimeno A, Donehower RC, Murphy KM, Hidalgo M, Baker SD, Messersmith WA. Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer. Invest New Drugs 2011;29:1057-65. [PMID: 20306339 DOI: 10.1007/s10637-010-9413-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
88 Sultana A, Shore S, Raraty MG, Vinjamuri S, Evans JE, Smith CT, Lane S, Chauhan S, Bosonnet L, Garvey C, Sutton R, Neoptolemos JP, Ghaneh P. Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I(131) KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma. BMC Cancer 2009;9:66. [PMID: 19243606 DOI: 10.1186/1471-2407-9-66] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
89 Abendroth A, Noureddine R, Abramczyk M, Paul A, Gerken G, Schmid KW, Markus P, Schumacher B, Wiesweg M, Köhler J, Markus M, Mende B, Dechêne A, Schuler M, Kasper S. Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols. J Cancer Res Clin Oncol 2019;145:445-55. [PMID: 30430229 DOI: 10.1007/s00432-018-2789-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
90 Weickhardt A, Michael M. Pancreatic cancer: advances in medical therapy. Expert Rev Clin Pharmacol 2009;2:173-80. [PMID: 24410649 DOI: 10.1586/17512433.2.2.173] [Reference Citation Analysis]
91 Soo RA, Yong WP, Innocenti F. Systemic therapies for pancreatic cancer--the role of pharmacogenetics. Curr Drug Targets 2012;13:811-28. [PMID: 22458528 DOI: 10.2174/138945012800564068] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
92 Chien W, Sun QY, Lee KL, Ding LW, Wuensche P, Torres-Fernandez LA, Tan SZ, Tokatly I, Zaiden N, Poellinger L, Mori S, Yang H, Tyner JW, Koeffler HP. Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer. Mol Oncol 2015;9:889-905. [PMID: 25637283 DOI: 10.1016/j.molonc.2015.01.002] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 5.4] [Reference Citation Analysis]
93 Guo S, Fesler A, Wang H, Ju J. microRNA based prognostic biomarkers in pancreatic Cancer. Biomark Res 2018;6:18. [PMID: 29942514 DOI: 10.1186/s40364-018-0131-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
94 Slapak EJ, Duitman J, Tekin C, Bijlsma MF, Spek CA. Matrix Metalloproteases in Pancreatic Ductal Adenocarcinoma: Key Drivers of Disease Progression? Biology (Basel) 2020;9:E80. [PMID: 32325664 DOI: 10.3390/biology9040080] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
95 Zheng YB, Zhang MR, Li Y, Liu XJ, Zhen YS. DBDx-based drug combinations show highly potent therapeutic efficacy against human pancreatic cancer xenografts in athymic mice. Cancer Biol Ther 2020;21:749-57. [PMID: 32644888 DOI: 10.1080/15384047.2020.1776580] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
96 Yamaue H, Tsunoda T, Tani M, Miyazawa M, Yamao K, Mizuno N, Okusaka T, Ueno H, Boku N, Fukutomi A, Ishii H, Ohkawa S, Furukawa M, Maguchi H, Ikeda M, Togashi Y, Nishio K, Ohashi Y. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study. Cancer Sci 2015;106:883-90. [PMID: 25867139 DOI: 10.1111/cas.12674] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 6.6] [Reference Citation Analysis]
97 Chiu J, Yau T. Metastatic pancreatic cancer: are we making progress in treatment. Gastroenterol Res Pract. 2012;2012:898931. [PMID: 23304129 DOI: 10.1155/2012/898931] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
98 Lv W, Yan T, Wang G, Zhao W, Zhang T, Zhou D. High-intensity focused ultrasound therapy in combination with gemcitabine for unresectable pancreatic carcinoma. Ther Clin Risk Manag 2016;12:687-91. [PMID: 27194912 DOI: 10.2147/TCRM.S90567] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
99 Kim EJ, Semrad TJ, Bold RJ. Phase II clinical trials on investigational drugs for the treatment of pancreatic cancers. Expert Opin Investig Drugs. 2015;24:781-794. [PMID: 25809274 DOI: 10.1517/13543784.2015.1026963] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
100 Furuse J, Gemma A, Ichikawa W, Okusaka T, Seki A, Ishii T. Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis. Jpn J Clin Oncol 2017;47:832-9. [PMID: 28541474 DOI: 10.1093/jjco/hyx075] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
101 D'Angiolella V, Esencay M, Pagano M. A cyclin without cyclin-dependent kinases: cyclin F controls genome stability through ubiquitin-mediated proteolysis. Trends Cell Biol 2013;23:135-40. [PMID: 23182110 DOI: 10.1016/j.tcb.2012.10.011] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 5.4] [Reference Citation Analysis]
102 Stainthorpe A, Greenhalgh J, Bagust A, Richardson M, Boland A, Beale S, Duarte R, Kotas E, Banks L, Palmer D. Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics 2018;36:1153-63. [PMID: 29600384 DOI: 10.1007/s40273-018-0646-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
103 Tempero MA, Arnoletti JP, Behrman S, Ben-Josef E, Benson AB 3rd, Berlin JD, Cameron JL, Casper ES, Cohen SJ, Duff M, Ellenhorn JD, Hawkins WG, Hoffman JP, Kuvshinoff BW 2nd, Malafa MP, Muscarella P 2nd, Nakakura EK, Sasson AR, Thayer SP, Tyler DS, Warren RS, Whiting S, Willett C, Wolff RA; NCCN Pancreatic Adenocarcinoma. Pancreatic adenocarcinoma. J Natl Compr Canc Netw 2010;8:972-1017. [PMID: 20876541 DOI: 10.6004/jnccn.2010.0073] [Cited by in Crossref: 122] [Cited by in F6Publishing: 111] [Article Influence: 10.2] [Reference Citation Analysis]
104 Lai HL, Chen YY, Lu CH, Hung CY, Kuo YC, Chen JS, Hsu HC, Chen PT, Chang PH, Hung YS, Chou WC. Effect of S-1 on survival outcomes in 838 patients with advanced pancreatic cancer: A 7-year multicenter observational cohort study in Taiwan. Cancer Med 2019;8:2085-94. [PMID: 31001907 DOI: 10.1002/cam4.2094] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
105 Nishikubo M, Shimomura Y, Hiramoto N, Sawamura N, Yamaguchi T, Hara S, Ishikawa T. Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report. BMC Nephrol 2021;22:175. [PMID: 33980166 DOI: 10.1186/s12882-021-02386-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Hwang IG, Jang JS, Oh SY, Lee S, Kwon HC, Lee GW, Go S, Kang MH, Cha YJ, Kang JH. A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer. Invest New Drugs 2012;30:2371-6. [PMID: 22302349 DOI: 10.1007/s10637-012-9792-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
107 Teague A, Lim KH, Wang-Gillam A. Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies. Ther Adv Med Oncol 2015;7:68-84. [PMID: 25755680 DOI: 10.1177/1758834014564775] [Cited by in Crossref: 86] [Cited by in F6Publishing: 83] [Article Influence: 12.3] [Reference Citation Analysis]
108 Walsh N, Kennedy S, Larkin A, Corkery B, O’Driscoll L, Clynes M, Crown J, O’Donovan N. EGFR and HER2 inhibition in pancreatic cancer. Invest New Drugs. 2013;31:558-566. [PMID: 23076814 DOI: 10.1007/s10637-012-9891-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
109 Carvajal RD, Tse A, Shah MA, Lefkowitz RA, Gonen M, Gilman-Rosen L, Kortmansky J, Kelsen DP, Schwartz GK, O’Reilly EM. A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer. Pancreatology. 2009;9:404-409. [PMID: 19451750 DOI: 10.1159/000187135] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
110 Obrist F, Michels J, Durand S, Chery A, Pol J, Levesque S, Joseph A, Astesana V, Pietrocola F, Wu GS, Castedo M, Kroemer G. Metabolic vulnerability of cisplatin-resistant cancers. EMBO J 2018;37:e98597. [PMID: 29875130 DOI: 10.15252/embj.201798597] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 10.3] [Reference Citation Analysis]
111 Golan T, Kanji ZS, Epelbaum R, Devaud N, Dagan E, Holter S, Aderka D, Paluch-Shimon S, Kaufman B, Gershoni-Baruch R, Hedley D, Moore MJ, Friedman E, Gallinger S. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer 2014;111:1132-8. [PMID: 25072261 DOI: 10.1038/bjc.2014.418] [Cited by in Crossref: 202] [Cited by in F6Publishing: 189] [Article Influence: 25.3] [Reference Citation Analysis]
112 Guo XZ, Cui ZM, Liu X. Current developments, problems and solutions in the non-surgical treatment of pancreatic cancer. World J Gastrointest Oncol 2013; 5(2): 20-28 [PMID: 23556053 DOI: 10.4251/wjgo.v5.i2.20] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
113 Hamada T, Nakai Y, Yasunaga H, Isayama H, Matsui H, Takahara N, Sasaki T, Takagi K, Watanabe T, Yagioka H, Kogure H, Arizumi T, Yamamoto N, Ito Y, Hirano K, Tsujino T, Tada M, Koike K. Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy. Br J Cancer 2014;110:1943-9. [PMID: 24642625 DOI: 10.1038/bjc.2014.131] [Cited by in Crossref: 35] [Cited by in F6Publishing: 41] [Article Influence: 4.4] [Reference Citation Analysis]
114 Lee JT, Campbell DO, Satyamurthy N, Czernin J, Radu CG. Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine PET. J Nucl Med 2012;53:275-80. [PMID: 22302964 DOI: 10.2967/jnumed.111.090407] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
115 Blanco VM, Latif T, Chu Z, Qi X. Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles. Transl Oncol 2015;8:196-203. [PMID: 26055177 DOI: 10.1016/j.tranon.2015.03.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
116 Tas F, Sen F, Odabas H, Kılıc L, Keskın S, Yıldız I. Performance status of patients is the major prognostic factor at all stages of pancreatic cancer. Int J Clin Oncol 2013;18:839-46. [PMID: 22996141 DOI: 10.1007/s10147-012-0474-9] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 5.4] [Reference Citation Analysis]
117 Grossberg AJ, Chu LC, Deig CR, Fishman EK, Hwang WL, Maitra A, Marks DL, Mehta A, Nabavizadeh N, Simeone DM, Weekes CD, Thomas CR Jr. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J Clin 2020;70:375-403. [PMID: 32683683 DOI: 10.3322/caac.21626] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 12.5] [Reference Citation Analysis]
118 Kang H, Jo JH, Lee HS, Chung MJ, Bang S, Park SW, Song SY, Park JY. Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer. World J Gastrointest Oncol 2018; 10(11): 421-430 [PMID: 30487953 DOI: 10.4251/wjgo.v10.i11.421] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
119 Blomstrand H, Batra A, Cheung WY, Elander NO. Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer. World J Clin Oncol 2021; 12(9): 787-799 [PMID: 34631442 DOI: 10.5306/wjco.v12.i9.787] [Reference Citation Analysis]
120 Blomstrand H, Scheibling U, Bratthäll C, Green H, Elander NO. Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer. BMC Cancer 2019;19:40. [PMID: 30621618 DOI: 10.1186/s12885-018-5244-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
121 Ter Veer E, van Rijssen LB, Besselink MG, Mali RMA, Berlin JD, Boeck S, Bonnetain F, Chau I, Conroy T, Van Cutsem E, Deplanque G, Friess H, Glimelius B, Goldstein D, Herrmann R, Labianca R, Van Laethem JL, Macarulla T, van der Meer JHM, Neoptolemos JP, Okusaka T, O'Reilly EM, Pelzer U, Philip PA, van der Poel MJ, Reni M, Scheithauer W, Siveke JT, Verslype C, Busch OR, Wilmink JW, van Oijen MGH, van Laarhoven HWM. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Lancet Oncol 2018;19:e151-60. [PMID: 29508762 DOI: 10.1016/S1470-2045(18)30098-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
122 Pahle J, Kobelt D, Aumann J, Behrens D, Daberkow O, Mokritzkij M, Piontek J, Stein U, Walther W. Effective Oncoleaking Treatment of Pancreatic Cancer by Claudin-Targeted Suicide Gene Therapy with Clostridium perfringens Enterotoxin (CPE). Cancers (Basel) 2021;13:4393. [PMID: 34503203 DOI: 10.3390/cancers13174393] [Reference Citation Analysis]
123 Malty AM, Jain SK, Yang PC, Harvey K, Warner JL. Computerized Approach to Creating a Systematic Ontology of Hematology/Oncology Regimens. JCO Clin Cancer Inform 2018;2. [PMID: 30238070 DOI: 10.1200/CCI.17.00142] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
124 Vaklavas C, Tsimberidou AM, Wen S, Hong D, Wheler J, Ng CS, Naing A, Uehara C, Wolff RA, Kurzrock R. Phase 1 clinical trials in 83 patients with pancreatic cancer: The M. D. Anderson Cancer Center experience. Cancer 2011;117:77-85. [PMID: 20737567 DOI: 10.1002/cncr.25346] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
125 Baechmann S, Ormanns S, Haas M, Kruger S, Remold A, Modest DP, Kirchner T, Jung A, Werner J, Heinemann V, Boeck S. Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research. BMC Cancer 2017;17:374. [PMID: 28549417 DOI: 10.1186/s12885-017-3376-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
126 Shah N, Zhai G, Knowles JA, Stockard CR, Grizzle WE, Fineberg N, Zhou T, Zinn KR, Rosenthal EL, Kim H. (18)F-FDG PET/CT imaging detects therapy efficacy of anti-EMMPRIN antibody and gemcitabine in orthotopic pancreatic tumor xenografts. Mol Imaging Biol 2012;14:237-44. [PMID: 21494920 DOI: 10.1007/s11307-011-0491-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
127 Li HY, Cui ZM, Chen J, Guo XZ, Li YY. Pancreatic cancer: diagnosis and treatments. Tumour Biol. 2015;36:1375-1384. [PMID: 25680410 DOI: 10.1007/s13277-015-3223-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
128 Heinemann V, Vehling-Kaiser U, Waldschmidt D, Kettner E, Märten A, Winkelmann C, Klein S, Kojouharoff G, Gauler TC, von Weikersthal LF, Clemens MR, Geissler M, Greten TF, Hegewisch-Becker S, Rubanov O, Baake G, Höhler T, Ko YD, Jung A, Neugebauer S, Boeck S. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104). Gut 2013;62:751-9. [PMID: 22773551 DOI: 10.1136/gutjnl-2012-302759] [Cited by in Crossref: 71] [Cited by in F6Publishing: 66] [Article Influence: 7.1] [Reference Citation Analysis]
129 Sultana A, Ghaneh P, Cunningham D, Starling N, Neoptolemos JP, Smith CT. Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison. BMC Cancer 2008;8:192. [PMID: 18611273 DOI: 10.1186/1471-2407-8-192] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
130 Jung YH, Choi HS, Cheon YK, Moon JH, Cho YD, Chang AR, Won JH. [An experience of cyberknife treatment in patients with advanced pancreaticobilliary malignancy]. Korean J Gastroenterol 2011;58:264-9. [PMID: 22113043 DOI: 10.4166/kjg.2011.58.5.264] [Reference Citation Analysis]
131 Ahn DH, Krishna K, Blazer M, Reardon J, Wei L, Wu C, Ciombor KK, Noonan AM, Mikhail S, Bekaii-Saab T. A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis. Ther Adv Med Oncol. 2017;9:75-82. [PMID: 28203300 DOI: 10.1177/1758834016676011] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
132 Min Y, Caster JM, Eblan MJ, Wang AZ. Clinical Translation of Nanomedicine. Chem Rev 2015;115:11147-90. [PMID: 26088284 DOI: 10.1021/acs.chemrev.5b00116] [Cited by in Crossref: 424] [Cited by in F6Publishing: 377] [Article Influence: 60.6] [Reference Citation Analysis]
133 Alexander A, Rehders A, Riediger R, Schmitt M, Anlauf M, Knoefel WT. Advanced Pancreatic Adenocarcinoma: Complete Histological Response After Palliative Therapy with Gemcitabine and Cisplatin. J Gastrointest Cancer 2012;43 Suppl 1:S42-5. [PMID: 22528322 DOI: 10.1007/s12029-012-9380-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
134 Zhou S, Yang Y, Yang Y, Tao H, Li D, Zhang J, Jiang G, Fang J. Combination therapy of VEGF-trap and gemcitabine results in improved anti-tumor efficacy in a mouse lung cancer model. PLoS One 2013;8:e68589. [PMID: 23874680 DOI: 10.1371/journal.pone.0068589] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
135 Scheithauer W, Ramanathan RK, Moore M, Macarulla T, Goldstein D, Hammel P, Kunzmann V, Liu H, McGovern D, Romano A. Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial. J Gastrointest Oncol. 2016;7:469-478. [PMID: 27284481 DOI: 10.21037/jgo.2016.01.03] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
136 De Vita F, Ventriglia J, Febbraro A, Laterza MM, Fabozzi A, Savastano B, Petrillo A, Diana A, Giordano G, Troiani T, Conzo G, Galizia G, Ciardiello F, Orditura M. NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice. BMC Cancer 2016;16:709. [PMID: 27590845 DOI: 10.1186/s12885-016-2671-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
137 Vaccaro V, Sperduti I, Vari S, Bria E, Melisi D, Garufi C, Nuzzo C, Scarpa A, Tortora G, Cognetti F, Reni M, Milella M. Metastatic pancreatic cancer: Is there a light at the end of the tunnel? World J Gastroenterol 2015; 21(16): 4788-4801 [PMID: 25944992 DOI: 10.3748/wjg.v21.i16.4788] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 44] [Article Influence: 6.4] [Reference Citation Analysis]
138 Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607-620. [PMID: 21620466 DOI: 10.1016/s0140-6736(10)62307-0] [Cited by in Crossref: 1377] [Cited by in F6Publishing: 849] [Article Influence: 125.2] [Reference Citation Analysis]
139 Kulke MH, Tempero MA, Niedzwiecki D, Hollis DR, Kindler HL, Cusnir M, Enzinger PC, Gorsch SM, Goldberg RM, Mayer RJ. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol. 2009;27:5506-5512. [PMID: 19858396 DOI: 10.1200/jco.2009.22.1309] [Cited by in Crossref: 58] [Cited by in F6Publishing: 32] [Article Influence: 4.5] [Reference Citation Analysis]
140 Morgan M, El Shaikh MA, Abu-Isa E, Davis MA, Lawrence TS. Radiosensitization by gemcitabine fixed-dose-rate infusion versus bolus injection in a pancreatic cancer model. Transl Oncol 2008;1:44-9. [PMID: 18607504 DOI: 10.1593/tlo.07118] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
141 Zheng YT, Yang HY, Li T, Zhao B, Shao TF, Xiang XQ, Cai WM. Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway. Acta Pharmacol Sin. 2015;36:614-626. [PMID: 25864651 DOI: 10.1038/aps.2015.4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
142 Koutsounas I, Giaginis C, Theocharis S. Histone deacetylase inhibitors and pancreatic cancer: Are there any promising clinical trials? World J Gastroenterol 2013; 19(8): 1173-1181 [PMID: 23482354 DOI: 10.3748/wjg.v19.i8.1173] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
143 Yu IS, Cheung WY. A Contemporary Review of the Treatment Landscape and the Role of Predictive and Prognostic Biomarkers in Pancreatic Adenocarcinoma. Can J Gastroenterol Hepatol 2018;2018:1863535. [PMID: 29623263 DOI: 10.1155/2018/1863535] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
144 İnal A, Kos FT, Algın E, Yıldız R, Berk V, Unek İT, Colak D, Dane F, Geredeli C, Isıkdogan A. Prognostic factors for gemcitabine-refractory patients with advanced pancreatic cancer: a retrospective analysis of a multicentre study (Anatolian Society of Medical Oncology). Contemp Oncol (Pozn) 2015;19:125-9. [PMID: 26034390 DOI: 10.5114/wo.2014.43933] [Reference Citation Analysis]
145 Tantoy IY, Cooper BA, Dhruva A, Cataldo J, Paul SM, Conley YP, Hammer M, Kober KM, Levine JD, Miaskowski C. Quality of life of patients with gastrointestinal cancers undergoing chemotherapy. Qual Life Res 2018;27:1865-76. [PMID: 29679368 DOI: 10.1007/s11136-018-1860-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
146 Martin LK, Li X, Kleiber B, Ellison EC, Bloomston M, Zalupski M, Bekaii-Saab TS. VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA. Ann Oncol. 2012;23:2812-2820. [PMID: 22767582 DOI: 10.1093/annonc/mds134] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
147 Boeck S, Hinke A, Wilkowski R, Heinemann V. Importance of performance status for treatment outcome in advanced pancreatic cancer. World J Gastroenterol 2007; 13(2): 224-227 [PMID: 17226900 DOI: 10.3748/wjg.v13.i2.224] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 42] [Article Influence: 3.1] [Reference Citation Analysis]
148 Lim JY, Cho JH, Lee SJ, Lee DK, Yoon DS, Cho JY. Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer. Cancer Res Treat. 2015;47:266-273. [PMID: 25327494 DOI: 10.4143/crt.2013.158] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
149 Schultheis B, Strumberg D, Bergmann L, Graeven U, Hanauske AR, Lipp R, Schuette J, Saito K, Scigalla P, Scheulen ME. Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group). Invest New Drugs. 2012;30:1184-1192. [PMID: 21484249 DOI: 10.1007/s10637-011-9665-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
150 Neesse A, Krug S, Gress TM, Tuveson DA, Michl P. Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma. Onco Targets Ther. 2013;7:33-43. [PMID: 24379681 DOI: 10.2147/ott.s38111] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
151 Sultana A, Tudur Smith C, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. Br J Cancer. 2008;99:6-13. [PMID: 18577990 DOI: 10.1038/sj.bjc.66 04436] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
152 Adamska A, Domenichini A, Falasca M. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. Int J Mol Sci. 2017;18. [PMID: 28640192 DOI: 10.3390/ijms18071338] [Cited by in Crossref: 210] [Cited by in F6Publishing: 198] [Article Influence: 42.0] [Reference Citation Analysis]
153 Lum LG, Thakur A, Choi M, Deol A, Kondadasula V, Schalk D, Fields K, Dufrense M, Philip P, Dyson G, Aon HD, Shields AF. Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients. Oncoimmunology 2020;9:1773201. [PMID: 32939319 DOI: 10.1080/2162402X.2020.1773201] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
154 Xia NX, Qiu BA, Wen JY, Zhu JY, Liu P. Therapeutic effect of two-pathway chemotherapy in combination with gamma-ray stereotactic radiotherapy on local advanced pancreatic cancer: an analysis of 12 cases. Shijie Huaren Xiaohua Zazhi 2009; 17(18): 1888-1893 [DOI: 10.11569/wcjd.v17.i18.1888] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
155 Wong W, Raufi AG, Safyan RA, Bates SE, Manji GA. BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects. Cancer Manag Res. 2020;12:2731-2742. [PMID: 32368150 DOI: 10.2147/cmar.s211151] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
156 Morgan MA, Parsels LA, Maybaum J, Lawrence TS. Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review. Clin Cancer Res 2008;14:6744-50. [PMID: 18980967 DOI: 10.1158/1078-0432.CCR-08-1032] [Cited by in Crossref: 43] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
157 Winer A, Handorf E, Dotan E. Dosing Schedules of Gemcitabine and nab-Paclitaxel for Older Adults With Metastatic Pancreatic Cancer. JNCI Cancer Spectr 2021;5:pkab074. [PMID: 34532641 DOI: 10.1093/jncics/pkab074] [Reference Citation Analysis]
158 Sugarbaker PH, Stuart OA. Intraperitoneal gemcitabine chemotherapy is safe for patients with resected pancreatic cancer: final clinical and pharmacologic data from a phase II protocol and recommended future directions. J Gastrointest Oncol 2021;12:S99-S109. [PMID: 33968430 DOI: 10.21037/jgo-2020-02] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
159 Chiorean EG, Coveler AL. Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. Drug Des Devel Ther. 2015;9:3529-3545. [PMID: 26185420 DOI: 10.2147/DDDT.S60328] [Cited by in Crossref: 74] [Cited by in F6Publishing: 48] [Article Influence: 10.6] [Reference Citation Analysis]
160 Haas M, Ormanns S, Baechmann S, Remold A, Kruger S, Westphalen CB, Siveke JT, Wenzel P, Schlitter AM, Esposito I, Quietzsch D, Clemens MR, Kettner E, Laubender RP, Jung A, Kirchner T, Boeck S, Heinemann V. Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer. Br J Cancer 2017;116:1462-9. [PMID: 28449008 DOI: 10.1038/bjc.2017.115] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
161 Gharaibeh M, McBride A, Alberts DS, Erstad B, Slack M, Alsaid N, Bootman JL, Abraham I. Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer. Pharmacoeconomics 2018;36:1333-43. [PMID: 29981004 DOI: 10.1007/s40273-018-0684-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
162 Wang Y, Hu GF, Zhang QQ, Tang N, Guo J, Liu LY, Han X, Wang X, Wang ZH. Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis. Drug Des Devel Ther. 2016;10:1961-1972. [PMID: 27358556 DOI: 10.2147/dddt.s105442] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
163 Jeon EK, Won HS, Ko YH, Lee IS, Hong TH, You YK, Lee MA. Comparison of the efficacy and the toxicity between gemcitabine with capecitabine (GC) and gemcitabine with erlotinib (GE) in unresectable pancreatic cancer. J Cancer Res Clin Oncol 2012;138:1625-30. [PMID: 22614154 DOI: 10.1007/s00432-012-1234-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
164 Hirooka Y, Kasuya H, Ishikawa T, Kawashima H, Ohno E, Villalobos IB, Naoe Y, Ichinose T, Koyama N, Tanaka M, Kodera Y, Goto H. A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer. BMC Cancer 2018;18:596. [PMID: 29801474 DOI: 10.1186/s12885-018-4453-z] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 12.8] [Reference Citation Analysis]
165 Awasthi N, Kirane A, Schwarz MA, Toombs JE, Brekken RA, Schwarz RE. Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer. BMC Cancer 2011;11:15. [PMID: 21226944 DOI: 10.1186/1471-2407-11-15] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
166 Bimonte S, Barbieri A, Leongito M, Piccirillo M, Giudice A, Pivonello C, de Angelis C, Granata V, Palaia R, Izzo F. Curcumin AntiCancer Studies in Pancreatic Cancer. Nutrients 2016;8:E433. [PMID: 27438851 DOI: 10.3390/nu8070433] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 8.2] [Reference Citation Analysis]
167 Tuli R, David J, Lobaugh S, Zhang Z, O'Reilly EM. Duration of therapy for locally advanced pancreatic cancer: Does it matter? Cancer Med 2020;9:4572-80. [PMID: 32368871 DOI: 10.1002/cam4.3081] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
168 Richards DA, Kuefler PR, Becerra C, Wilfong LS, Gersh RH, Boehm KA, Zhan F, Asmar L, Myrand SP, Hozak RR. Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study. Invest New Drugs. 2011;29:144-153. [PMID: 19714296 DOI: 10.1007/s10637-009-9307-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
169 Maréchal R, Puleo F, Demols A, Verset G, Laethem JV. Personalized medicine in pancreatic cancer: the revolution has begun. Per Med 2015;12:515-23. [PMID: 29749894 DOI: 10.2217/pme.15.15] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
170 Hentic O, Dreyer C, Rebours V, Zappa M, Lévy P, Raymond E, Ruszniewski P, Hammel P. Gemcitabine in elderly patients with advanced pancreatic cancer. World J Gastroenterol 2011; 17(30): 3497-3502 [PMID: 21941416 DOI: 10.3748/wjg.v17.i30.3497] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
171 Chang JS, Chiu YF, Yu JC, Chen LT, Ch'ang HJ. The Role of Consolidation Chemoradiotherapy in Locally Advanced Pancreatic Cancer Receiving Chemotherapy: An Updated Systematic Review and Meta-Analysis. Cancer Res Treat 2018;50:562-74. [PMID: 28602054 DOI: 10.4143/crt.2017.105] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
172 Gresham GK, Wells GA, Gill S, Cameron C, Jonker DJ. Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis. BMC Cancer 2014;14:471. [PMID: 24972449 DOI: 10.1186/1471-2407-14-471] [Cited by in Crossref: 77] [Cited by in F6Publishing: 70] [Article Influence: 9.6] [Reference Citation Analysis]
173 Ouyang G, Liu Z, Huang S, Li Q, Xiong L, Miao X, Wen Y. Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis. World J Surg Oncol 2016;14:59. [PMID: 26927942 DOI: 10.1186/s12957-016-0813-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
174 Soo RA, Yong WP, Innocenti F. Systemic therapies for pancreatic cancer--the role of pharmacogenetics. Curr Drug Targets. 2012;13:811-828. [PMID: 22458528 DOI: 10.1016/j.pestbp.2011.02.012.investigations] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
175 Mohammad J, Dhillon H, Chikara S, Mamidi S, Sreedasyam A, Chittem K, Orr M, Wilkinson JC, Reindl KM. Piperlongumine potentiates the effects of gemcitabine in in vitro and in vivo human pancreatic cancer models. Oncotarget 2018;9:10457-69. [PMID: 29535819 DOI: 10.18632/oncotarget.23623] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
176 Hu J, Zhao G, Wang HX, Tang L, Xu YC, Ma Y, Zhang FC. A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma. J Hematol Oncol 2011;4:11. [PMID: 21439076 DOI: 10.1186/1756-8722-4-11] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 3.8] [Reference Citation Analysis]
177 Gunturu KS, Yao X, Cong X, Thumar JR, Hochster HS, Stein SM, Lacy J. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. Med Oncol 2013;30. [DOI: 10.1007/s12032-012-0361-2] [Cited by in Crossref: 89] [Cited by in F6Publishing: 88] [Article Influence: 8.9] [Reference Citation Analysis]
178 Ferrone CR, Levine DA, Tang LH, Allen PJ, Jarnagin W, Brennan MF, Offit K, Robson ME. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol 2009;27:433-8. [PMID: 19064968 DOI: 10.1200/JCO.2008.18.5546] [Cited by in Crossref: 136] [Cited by in F6Publishing: 77] [Article Influence: 9.7] [Reference Citation Analysis]
179 Matsubara J, Ono M, Honda K, Negishi A, Ueno H, Okusaka T, Furuse J, Furuta K, Sugiyama E, Saito Y, Kaniwa N, Sawada J, Shoji A, Sakuma T, Chiba T, Saijo N, Hirohashi S, Yamada T. Survival prediction for pancreatic cancer patients receiving gemcitabine treatment. Mol Cell Proteomics 2010;9:695-704. [PMID: 20061307 DOI: 10.1074/mcp.M900234-MCP200] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
180 Ogata T, Satake H, Ogata M, Hatachi Y, Yasui H. Oxaliplatin-Induced Hyperammonemic Encephalopathy in a Patient with Metastatic Pancreatic Cancer: A Case Report. Case Rep Oncol 2017;10:885-9. [PMID: 29118705 DOI: 10.1159/000481398] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
181 Pathy S, Chander S. Chemoradiotherapy in pancreatic carcinoma. Indian J Med Paediatr Oncol. 2009;30:55-60. [PMID: 20596304 DOI: 10.4103/0971-5851.60049] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
182 De Jesus-Acosta A, Oliver GR, Blackford A, Kinsman K, Flores EI, Wilfong LS, Zheng L, Donehower RC, Cosgrove D, Laheru D. A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2012;69:415-424. [PMID: 21800112 DOI: 10.1007/s00280-011-1704-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
183 Park JK, Kim Y, Kim H, Jeon J, Kim TW, Park JH, Hwnag YI, Lee WJ, Kang JS. The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma. Oncotarget 2016;7:75081-93. [PMID: 27655706 DOI: 10.18632/oncotarget.12057] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
184 Ormanns S, Haas M, Baechmann S, Altendorf-Hofmann A, Remold A, Quietzsch D, Clemens MR, Bentz M, Geissler M, Lambertz H, Kruger S, Kirchner T, Heinemann V, Boeck S. Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials. Br J Cancer. 2016;115:1520-1529. [PMID: 27802454 DOI: 10.1038/bjc.2016.355] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
185 Ruess DA, Görgülü K, Wörmann SM, Algül H. Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts. Drugs Aging 2017;34:331-57. [PMID: 28349415 DOI: 10.1007/s40266-017-0453-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
186 Lei F, Xi X, Batra SK, Bronich TK. Combination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer. J Pharmacol Exp Ther 2019;370:682-94. [PMID: 30796131 DOI: 10.1124/jpet.118.255786] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
187 Liu F, Gore AJ, Wilson JL, Korc M. DUSP1 is a novel target for enhancing pancreatic cancer cell sensitivity to gemcitabine. PLoS One 2014;9:e84982. [PMID: 24409315 DOI: 10.1371/journal.pone.0084982] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
188 Yang ZY, Yuan JQ, Di MY, Zheng DY, Chen JZ, Ding H, Wu XY, Huang YF, Mao C, Tang JL. Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis. PLoS One. 2013;8:e57528. [PMID: 23472089 DOI: 10.1371/journal.pone.0057528] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
189 Huang CY, Ju DT, Chang CF, Muralidhar Reddy P, Velmurugan BK. A review on the effects of current chemotherapy drugs and natural agents in treating non-small cell lung cancer. Biomedicine (Taipei). 2017;7:23. [PMID: 29130448 DOI: 10.1051/bmdcn/2017070423] [Cited by in Crossref: 150] [Cited by in F6Publishing: 131] [Article Influence: 30.0] [Reference Citation Analysis]
190 Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs. 2008;26:463-471. [PMID: 18379729 DOI: 10.1007/s10637-008-9127-2] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 3.9] [Reference Citation Analysis]
191 Oberstein PE, Olive KP. Pancreatic cancer: why is it so hard to treat? Therap Adv Gastroenterol. 2013;6:321-337. [PMID: 23814611 DOI: 10.1177/1756283x13478680] [Cited by in Crossref: 155] [Cited by in F6Publishing: 104] [Article Influence: 17.2] [Reference Citation Analysis]
192 Kim M, Chin YW, Lee EJ. α, γ-Mangostins Induce Autophagy and Show Synergistic Effect with Gemcitabine in Pancreatic Cancer Cell Lines. Biomol Ther (Seoul) 2017;25:609-17. [PMID: 28822990 DOI: 10.4062/biomolther.2017.074] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
193 Hidalgo M, Abad A, Aranda E, Díez L, Feliu J, Gómez C, Irigoyen A, López R, Rivera F, Rubio C, Sastre J, Tabernero J, Díaz-Rubio E. Consensus on the treatment of pancreatic cancer in Spain. Clin Transl Oncol 2009;11:290-301. [PMID: 19451062 DOI: 10.1007/s12094-009-0357-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
194 Makohon-Moore A, Brosnan JA, Iacobuzio-Donahue CA. Pancreatic cancer genomics: insights and opportunities for clinical translation. Genome Med 2013;5:26. [PMID: 23673020 DOI: 10.1186/gm430] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
195 Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, Hruban RH. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63:318-348. [PMID: 23856911 DOI: 10.1002/caac.21190] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
196 Laquente B, Macarulla T, Bugés C, Martín M, García C, Pericay C, Merino S, Visa L, Martín T, Pedraza M, Carnero B, Guardeño R, Verdaguer H, Mut A, Vilanova D, García A. Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice. BMC Palliat Care 2020;19:103. [PMID: 32650765 DOI: 10.1186/s12904-020-00610-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
197 Lawrence B, Findlay M. Systemic therapy for metastatic pancreatic adenocarcinoma. Ther Adv Med Oncol 2010;2:85-106. [PMID: 21789129 DOI: 10.1177/1758834009357188] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
198 Deng GC, Sun DC, Zhou Q, Lv Y, Yan H, Han QL, Dai GH. Identification of DNA methylation-driven genes and construction of a nomogram to predict overall survival in pancreatic cancer. BMC Genomics 2021;22:791. [PMID: 34732125 DOI: 10.1186/s12864-021-08097-w] [Reference Citation Analysis]
199 Chan K, Shah K, Lien K, Coyle D, Lam H, Ko YJ. A Bayesian meta-analysis of multiple treatment comparisons of systemic regimens for advanced pancreatic cancer. PLoS One. 2014;9:e108749. [PMID: 25286060 DOI: 10.1371/journal.pone.0108749] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
200 Lee S, N Srinivasa R, A Rigberg D, Yanagawa J, Benharash P, M Moriarty J. Aortoesophageal fistula involving the central aortic arch salvaged with emergent percutaneous TEVAR, great vessel coverage and in vivo graft fenestration. Diagn Interv Radiol 2021;27:122-5. [PMID: 33290236 DOI: 10.5152/dir.2020.20033] [Reference Citation Analysis]
201 Chin V, Nagrial A, Sjoquist K, O'Connor CA, Chantrill L, Biankin AV, Scholten RJ, Yip D. Chemotherapy and radiotherapy for advanced pancreatic cancer. Cochrane Database Syst Rev 2018;3:CD011044. [PMID: 29557103 DOI: 10.1002/14651858.CD011044.pub2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 30] [Article Influence: 5.5] [Reference Citation Analysis]
202 Moinpour CM, Vaught NL, Goldman B, Redman MW, Philip PA, Millwood B, Lippman SM, Seay TE, Flynn PJ, O'Reilly EM. Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer. J Clin Oncol. 2010;28:3611-3616. [PMID: 20606094 DOI: 10.1200/JCO.2009.25.8285] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
203 Khalil MA, Qiao W, Carlson P, George B, Javle M, Overman M, Varadhachary G, Wolff RA, Abbruzzese JL, Fogelman DR. The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. Invest New Drugs. 2013;31:1375-1383. [PMID: 23645398 DOI: 10.1007/s10637-013-9967-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
204 Kanai M. Therapeutic applications of curcumin for patients with pancreatic cancer. World J Gastroenterol 2014; 20(28): 9384-9391 [PMID: 25071333 DOI: 10.3748/wjg.v20.i28.9384] [Cited by in F6Publishing: 33] [Reference Citation Analysis]
205 Korkeila EA. Advanced pancreatic cancer - how to choose an adequate treatment option. World J Gastroenterol 2015; 21(38): 10709-10713 [PMID: 26478662 DOI: 10.3748/wjg.v21.i38.10709] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
206 Xu J, Singh A, Amiji MM. Redox-responsive targeted gelatin nanoparticles for delivery of combination wt-p53 expressing plasmid DNA and gemcitabine in the treatment of pancreatic cancer. BMC Cancer. 2014;14:75. [PMID: 24507760 DOI: 10.1186/1471-2407-14-75] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
207 Chou WC, Chen YY, Hung CY, Chen JS, Lu CH, Chang PH. Evolution of the chemotherapeutic landscape and survival outcome in patients with metastatic pancreatic cancer: a four-institute cohort study in Taiwan, 2010-2016. Cancer Manag Res 2019;11:2119-27. [PMID: 30936744 DOI: 10.2147/CMAR.S196300] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
208 Castellanos E, Berlin J, Cardin DB. Current treatment options for pancreatic carcinoma. Curr Oncol Rep 2011;13:195-205. [PMID: 21491194 DOI: 10.1007/s11912-011-0164-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
209 Kim MP, Truty MJ, Choi W, Kang Y, Chopin-Lally X, Gallick GE, Wang H, McConkey DJ, Hwang R, Logsdon C, Abbruzzesse J, Fleming JB. Molecular profiling of direct xenograft tumors established from human pancreatic adenocarcinoma after neoadjuvant therapy. Ann Surg Oncol 2012;19 Suppl 3:S395-403. [PMID: 21701930 DOI: 10.1245/s10434-011-1839-4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
210 Lee HS, Park SW. Systemic Chemotherapy in Advanced Pancreatic Cancer. Gut Liver 2016;10:340-7. [PMID: 27114434 DOI: 10.5009/gnl15465] [Cited by in Crossref: 27] [Cited by in F6Publishing: 37] [Article Influence: 5.4] [Reference Citation Analysis]
211 Khalafalla FG, Khan MW. Inflammation and Epithelial-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma: Fighting Against Multiple Opponents. Cancer Growth Metastasis. 2017;10:1179064417709287. [PMID: 28579826 DOI: 10.1177/1179064417709287] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
212 Pino MS, Balsamo M, Di Modugno F, Mottolese M, Alessio M, Melucci E, Milella M, McConkey DJ, Philippar U, Gertler FB, Natali PG, Nisticò P. Human Mena+11a isoform serves as a marker of epithelial phenotype and sensitivity to epidermal growth factor receptor inhibition in human pancreatic cancer cell lines. Clin Cancer Res 2008;14:4943-50. [PMID: 18676769 DOI: 10.1158/1078-0432.CCR-08-0436] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 3.4] [Reference Citation Analysis]
213 Dahan L, Bonnetain F, Ychou M, Mitry E, Gasmi M, Raoul JL, Cattan S, Phelip JM, Hammel P, Chauffert B, Michel P, Legoux JL, Rougier P, Bedenne L, Seitz JF; Fédération Francophone de Cancérologie Digestive. Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). Gut 2010;59:1527-34. [PMID: 20947887 DOI: 10.1136/gut.2010.216135] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 4.6] [Reference Citation Analysis]
214 Kessler ER, Eckhardt SG, Pitts TM, Bradshaw-Pierce EL, O'byrant CL, Messersmith WA, Nallapreddy S, Weekes C, Spratlin J, Lieu CH, Kane MA, Eppers S, Freas E, Leong S. Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers. Invest New Drugs 2016;34:176-83. [PMID: 26715573 DOI: 10.1007/s10637-015-0316-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
215 Lim SH, Yun J, Lee MY, Kim HJ, Kim KH, Kim SH, Lee SC, Bae SB, Kim CK, Lee N, Lee KT, Park SK, Lee YN, Moon JH. Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial. Yonsei Med J 2021;62:671-8. [PMID: 34296544 DOI: 10.3349/ymj.2021.62.8.671] [Reference Citation Analysis]
216 Giuliani J, Bonetti A. FOLFIRINOX is a cost-effective combination chemotherapy in first-line for advanced pancreatic Cancer. Pancreatology 2019;19:325-30. [DOI: 10.1016/j.pan.2019.01.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
217 Bayraktar S, Bayraktar UD, Rocha-Lima CM. Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer. World J Gastroenterol 2010; 16(6): 673-682 [PMID: 20135714 DOI: 10.3748/wjg.v16.i6.673] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
218 Sultana A, Tudur Smith C, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. Br J Cancer. 2008;99:6-13. [PMID: 18577990 DOI: 10.1038/sj.bjc.6604436] [Cited by in Crossref: 70] [Cited by in F6Publishing: 66] [Article Influence: 5.0] [Reference Citation Analysis]
219 Sun C, Ansari D, Andersson R, Wu DQ. Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer? World J Gastroenterol 2012; 18(35): 4944-4958 [PMID: 23002368 DOI: 10.3748/wjg.v18.i35.4944] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 48] [Article Influence: 4.7] [Reference Citation Analysis]
220 Caparello C, Meijer LL, Garajova I, Falcone A, Le Large TY, Funel N, Kazemier G, Peters GJ, Vasile E, Giovannetti E. FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. World J Gastroenterol 2016; 22(31): 6987-7005 [PMID: 27610011 DOI: 10.3748/wjg.v22.i31.6987] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
221 Hamada S, Masamune A, Shimosegawa T. Novel therapeutic strategies targeting tumor-stromal interactions in pancreatic cancer. Front Physiol 2013;4:331. [PMID: 24273517 DOI: 10.3389/fphys.2013.00331] [Cited by in Crossref: 20] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
222 Xue P, Zhu L, Wan Z, Huang W, Li N, Chen D, Hu J, Yang H, Wang L. A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative chemotherapy. J Cancer Res Clin Oncol 2015;141:1653-60. [PMID: 25792009 DOI: 10.1007/s00432-015-1953-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
223 Beer M, Kuppalu N, Stefanini M, Becker H, Schulz I, Manoli S, Schuette J, Schmees C, Casazza A, Stelzle M, Arcangeli A. A novel microfluidic 3D platform for culturing pancreatic ductal adenocarcinoma cells: comparison with in vitro cultures and in vivo xenografts. Sci Rep 2017;7:1325. [PMID: 28465513 DOI: 10.1038/s41598-017-01256-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
224 Sharma MR, Stadler WM, Ratain MJ. Randomized phase II trials: a long-term investment with promising returns. J Natl Cancer Inst 2011;103:1093-100. [PMID: 21709274 DOI: 10.1093/jnci/djr218] [Cited by in Crossref: 61] [Cited by in F6Publishing: 51] [Article Influence: 5.5] [Reference Citation Analysis]
225 Varghese AM, Lowery MA, Yu KH, O'Reilly EM. Current management and future directions in metastatic pancreatic adenocarcinoma. Cancer 2016;122:3765-75. [PMID: 27649047 DOI: 10.1002/cncr.30342] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
226 Boswell-Casteel RC, Hays FA. Equilibrative nucleoside transporters-A review. Nucleosides Nucleotides Nucleic Acids 2017;36:7-30. [PMID: 27759477 DOI: 10.1080/15257770.2016.1210805] [Cited by in Crossref: 75] [Cited by in F6Publishing: 66] [Article Influence: 12.5] [Reference Citation Analysis]